Immunotherapy Vaccines for Prostate Cancer Treatment
ABSTRACT Background Therapeutic tumor vaccines have emerged as a compelling avenue for treating patients afflicted with advanced prostate cancer (PCa), particularly those experiencing biochemical relapse or ineligible for surgical intervention. This study serves to consolidate recent research findin...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70294 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850181053976674304 |
|---|---|
| author | Jide He Jialong Wu Ziang Li Zhenkun Zhao Lei Qiu Xuehua Zhu Zenan Liu Haizhui Xia Peng Hong Jianling Yang Ling Ni Jian Lu |
| author_facet | Jide He Jialong Wu Ziang Li Zhenkun Zhao Lei Qiu Xuehua Zhu Zenan Liu Haizhui Xia Peng Hong Jianling Yang Ling Ni Jian Lu |
| author_sort | Jide He |
| collection | DOAJ |
| description | ABSTRACT Background Therapeutic tumor vaccines have emerged as a compelling avenue for treating patients afflicted with advanced prostate cancer (PCa), particularly those experiencing biochemical relapse or ineligible for surgical intervention. This study serves to consolidate recent research findings on therapeutic vaccines targeting prostate tumors while delineating prevalent challenges within vaccine research and development. Methods We searched electronic databases, including PubMed, Web of Science, Embase, and Scopus, up to August 31, 2024, using keywords such as 'vaccine', 'prostate cancer', 'immunotherapy', and others. We reviewed studies on various therapeutic vaccines, including dendritic cell‐based, antigen, nucleic acid, and tumor cell vaccines. Results Studies consistently showed that therapeutic vaccines, notably DC vaccines, had favorable safety profiles with few adverse effects. These vaccines, with varied antigenic formulations, demonstrated strong clinical outcomes, as indicated by metrics such as PSA response rates (9.5%‐58%), extended PSA doubling times (52.9%–89.7%), overall survival durations (17.7–33.8 months), two‐year mortality rates (0%–12.5%), biochemical relapse rates (42%–73%), and antigen‐specific immune responses (33.3%–71.4% in responsive groups). Conclusion While clinical data for tumor vaccines have illuminated robust evidence of tumoricidal activity, the processes of their formulation and deployment are riddled with complexities. Combining vaccines with other therapies may enhance outcomes, and future research should focus on early interventions and deciphering the immune system's role in oncogenesis. |
| format | Article |
| id | doaj-art-5dab1a8cb2f94f5d9da8cc828106f0c1 |
| institution | OA Journals |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-5dab1a8cb2f94f5d9da8cc828106f0c12025-08-20T02:17:59ZengWileyCancer Medicine2045-76342024-10-011320n/an/a10.1002/cam4.70294Immunotherapy Vaccines for Prostate Cancer TreatmentJide He0Jialong Wu1Ziang Li2Zhenkun Zhao3Lei Qiu4Xuehua Zhu5Zenan Liu6Haizhui Xia7Peng Hong8Jianling Yang9Ling Ni10Jian Lu11Department of Urology Peking University Third Hospital Beijing ChinaDepartment of Urology Peking University Third Hospital Beijing ChinaDepartment of Urology Peking University Third Hospital Beijing ChinaDepartment of Urology Peking University Third Hospital Beijing ChinaDepartment of Urology Peking University Third Hospital Beijing ChinaDepartment of Urology Peking University Third Hospital Beijing ChinaDepartment of Urology Peking University Third Hospital Beijing ChinaDepartment of Urology Peking University Third Hospital Beijing ChinaDepartment of Urology Peking University Third Hospital Beijing ChinaInstitute of Medical Innovation and Research Peking University Third Hospital Beijing ChinaInstitute for Immunology and School of Medicine Tsinghua University, Medical Research Building Beijing ChinaDepartment of Urology Peking University Third Hospital Beijing ChinaABSTRACT Background Therapeutic tumor vaccines have emerged as a compelling avenue for treating patients afflicted with advanced prostate cancer (PCa), particularly those experiencing biochemical relapse or ineligible for surgical intervention. This study serves to consolidate recent research findings on therapeutic vaccines targeting prostate tumors while delineating prevalent challenges within vaccine research and development. Methods We searched electronic databases, including PubMed, Web of Science, Embase, and Scopus, up to August 31, 2024, using keywords such as 'vaccine', 'prostate cancer', 'immunotherapy', and others. We reviewed studies on various therapeutic vaccines, including dendritic cell‐based, antigen, nucleic acid, and tumor cell vaccines. Results Studies consistently showed that therapeutic vaccines, notably DC vaccines, had favorable safety profiles with few adverse effects. These vaccines, with varied antigenic formulations, demonstrated strong clinical outcomes, as indicated by metrics such as PSA response rates (9.5%‐58%), extended PSA doubling times (52.9%–89.7%), overall survival durations (17.7–33.8 months), two‐year mortality rates (0%–12.5%), biochemical relapse rates (42%–73%), and antigen‐specific immune responses (33.3%–71.4% in responsive groups). Conclusion While clinical data for tumor vaccines have illuminated robust evidence of tumoricidal activity, the processes of their formulation and deployment are riddled with complexities. Combining vaccines with other therapies may enhance outcomes, and future research should focus on early interventions and deciphering the immune system's role in oncogenesis.https://doi.org/10.1002/cam4.70294immunotherapyprognosisprostate cancertherapeutic tumor vaccinetumor treatment |
| spellingShingle | Jide He Jialong Wu Ziang Li Zhenkun Zhao Lei Qiu Xuehua Zhu Zenan Liu Haizhui Xia Peng Hong Jianling Yang Ling Ni Jian Lu Immunotherapy Vaccines for Prostate Cancer Treatment Cancer Medicine immunotherapy prognosis prostate cancer therapeutic tumor vaccine tumor treatment |
| title | Immunotherapy Vaccines for Prostate Cancer Treatment |
| title_full | Immunotherapy Vaccines for Prostate Cancer Treatment |
| title_fullStr | Immunotherapy Vaccines for Prostate Cancer Treatment |
| title_full_unstemmed | Immunotherapy Vaccines for Prostate Cancer Treatment |
| title_short | Immunotherapy Vaccines for Prostate Cancer Treatment |
| title_sort | immunotherapy vaccines for prostate cancer treatment |
| topic | immunotherapy prognosis prostate cancer therapeutic tumor vaccine tumor treatment |
| url | https://doi.org/10.1002/cam4.70294 |
| work_keys_str_mv | AT jidehe immunotherapyvaccinesforprostatecancertreatment AT jialongwu immunotherapyvaccinesforprostatecancertreatment AT ziangli immunotherapyvaccinesforprostatecancertreatment AT zhenkunzhao immunotherapyvaccinesforprostatecancertreatment AT leiqiu immunotherapyvaccinesforprostatecancertreatment AT xuehuazhu immunotherapyvaccinesforprostatecancertreatment AT zenanliu immunotherapyvaccinesforprostatecancertreatment AT haizhuixia immunotherapyvaccinesforprostatecancertreatment AT penghong immunotherapyvaccinesforprostatecancertreatment AT jianlingyang immunotherapyvaccinesforprostatecancertreatment AT lingni immunotherapyvaccinesforprostatecancertreatment AT jianlu immunotherapyvaccinesforprostatecancertreatment |